ArticleOncogene2026
Single‑cell multi‑omics analysis reveals TGF-β1-RUNX2-mediated matCAF differentiation and its role in remodeling the lymph node metastatic microenvironment in bladder cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymph node metastasis (LNM) in bladder cancer (BCa) is associated with poor clinical outcomes and may contribute to the development of metastatic tolerance, yet the stromal mechanisms underlying this process remain incompletely understood. By integrating single-cell RNA sequencing, spatial transcriptomics, clinical cohorts, and functional models, we identified an LNM-enriched matrix-remodeling cancer-associated fibroblast (matCAF) state characterized by LRRC15 and POSTN expression and associated with adverse survival and reduced immunotherapy response. Mechanistically, Hybrid_CCND1⁺ malignant epithelial cells promoted matCAF differentiation through FOS-dependent TGFB1 transcription and TGF-β1-TGFBR1-RUNX2 signaling. Spatial analyses further revealed barrier-like accumulation of matCAFs at tumor-stroma interfaces and linked matCAF-rich neighborhoods to enhanced PI3K activity and lymphangiogenesis-related programs. Functionally, matCAF-derived POSTN engaged ITGAV/ITGB5 to activate PI3K-AKT signaling and promote tumor and lymphatic endothelial remodeling. MatCAFs were also associated with SPP1⁺ macrophage remodeling and impaired CD8⁺ T-cell function, partly through RUNX2-associated CXCL12-CXCR4 signaling. Pharmacological disruption of the RUNX2-dependent matCAF program reduced tumor burden and partially restored T-cell activity in vivo. Collectively, these findings identify matCAF-centered stromal remodeling as a potential cellular basis of the metastatic-tolerance niche in BCa LNM and provide proof-of-concept for therapeutic targeting of the matCAF program.
Identifiers
42918833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.